BG107613A - Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена - Google Patents

Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена Download PDF

Info

Publication number: BG107613A
Authority: BG; Bulgaria
Prior art keywords: region; polypeptide; tnf; seq; amino acid
Prior art date: 2000-09-15

Application number

BG107613A

Other languages

Bulgarian (bg)

English (en)

Inventor

Thomas Wust

Dieter Moosmayer

Matthias Grell

Peter Scheurich

Original Assignee

Universitat Stuttgart

Pfizenmaier Klaus

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2003-03-06

Publication date

2003-12-31

2003-03-06 Application filed by Universitat Stuttgart, Pfizenmaier Klaus filed Critical Universitat Stuttgart

2003-12-31 Publication of BG107613A publication Critical patent/BG107613A/bg

Links

230000003993 interaction Effects 0.000 title claims description 4
229940002612 prodrug Drugs 0.000 title description 49
239000000651 prodrug Substances 0.000 title description 49
108020001507 fusion proteins Proteins 0.000 title description 10
102000037865 fusion proteins Human genes 0.000 title description 10
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 59
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 44
229920001184 polypeptide Polymers 0.000 claims abstract description 43
210000004027 cell Anatomy 0.000 claims abstract description 41
238000012545 processing Methods 0.000 claims abstract description 18
230000004071 biological effect Effects 0.000 claims abstract description 9
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 7
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 7
210000002744 extracellular matrix Anatomy 0.000 claims abstract description 7
102000004127 Cytokines Human genes 0.000 claims abstract description 6
108090000695 Cytokines Proteins 0.000 claims abstract description 6
238000001727 in vivo Methods 0.000 claims abstract description 5
229920002521 macromolecule Polymers 0.000 claims abstract description 4
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 55
125000000539 amino acid group Chemical group 0.000 claims description 32
206010028980 Neoplasm Diseases 0.000 claims description 27
238000003776 cleavage reaction Methods 0.000 claims description 27
239000012634 fragment Substances 0.000 claims description 27
230000007017 scission Effects 0.000 claims description 25
230000027455 binding Effects 0.000 claims description 22
108091005804 Peptidases Proteins 0.000 claims description 20
239000004365 Protease Substances 0.000 claims description 19
239000013598 vector Substances 0.000 claims description 14
125000003275 alpha amino acid group Chemical group 0.000 claims description 13
108020004707 nucleic acids Proteins 0.000 claims description 13
102000039446 nucleic acids Human genes 0.000 claims description 13
150000007523 nucleic acids Chemical class 0.000 claims description 13
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 12
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 12
229960000187 tissue plasminogen activator Drugs 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 11
102000005962 receptors Human genes 0.000 claims description 9
108020003175 receptors Proteins 0.000 claims description 9
238000005829 trimerization reaction Methods 0.000 claims description 9
230000033115 angiogenesis Effects 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
125000003729 nucleotide group Chemical group 0.000 claims description 7
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
239000002773 nucleotide Substances 0.000 claims description 6
239000001963 growth medium Substances 0.000 claims description 5
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
102000057041 human TNF Human genes 0.000 claims description 4
230000008807 pathological lesion Effects 0.000 claims description 4
210000004881 tumor cell Anatomy 0.000 claims description 4
102000003675 cytokine receptors Human genes 0.000 claims description 3
108010057085 cytokine receptors Proteins 0.000 claims description 3
210000002889 endothelial cell Anatomy 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
239000011159 matrix material Substances 0.000 claims description 3
230000036961 partial effect Effects 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
230000000890 antigenic effect Effects 0.000 claims description 2
239000003114 blood coagulation factor Substances 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
210000000170 cell membrane Anatomy 0.000 claims description 2
230000001808 coupling effect Effects 0.000 claims description 2
238000010168 coupling process Methods 0.000 claims description 2
238000005859 coupling reaction Methods 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
210000003527 eukaryotic cell Anatomy 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
210000001236 prokaryotic cell Anatomy 0.000 claims description 2
230000002062 proliferating effect Effects 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
102000005741 Metalloproteases Human genes 0.000 claims 1
108010006035 Metalloproteases Proteins 0.000 claims 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
108010067390 Viral Proteins Proteins 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
230000001338 necrotic effect Effects 0.000 claims 1
210000001685 thyroid gland Anatomy 0.000 claims 1
230000000259 anti-tumor effect Effects 0.000 abstract description 6
230000002519 immonomodulatory effect Effects 0.000 abstract description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 51
102000035195 Peptidases Human genes 0.000 description 18
108090000631 Trypsin Proteins 0.000 description 14
102000004142 Trypsin Human genes 0.000 description 14
239000012588 trypsin Substances 0.000 description 14
230000014509 gene expression Effects 0.000 description 13
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
102000003298 tumor necrosis factor receptor Human genes 0.000 description 11
235000018102 proteins Nutrition 0.000 description 10
230000004913 activation Effects 0.000 description 9
230000000694 effects Effects 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
102100021935 C-C motif chemokine 26 Human genes 0.000 description 6
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
239000000499 gel Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000001262 western blot Methods 0.000 description 5
102000007000 Tenascin Human genes 0.000 description 4
108010008125 Tenascin Proteins 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000006882 induction of apoptosis Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
101100425753 Homo sapiens TNFRSF1A gene Proteins 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 3
230000009471 action Effects 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000002184 metal Substances 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
241000235058 Komagataella pastoris Species 0.000 description 2
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
101100497483 Mus musculus Csrp1 gene Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
101100054070 Rattus norvegicus Andpro gene Proteins 0.000 description 2
101100059590 Rattus norvegicus Cebpe gene Proteins 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
108010072257 fibroblast activation protein alpha Proteins 0.000 description 2
238000000227 grinding Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102100038083 Endosialin Human genes 0.000 description 1
101710144543 Endosialin Proteins 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
102100024025 Heparanase Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
101001104566 Homo sapiens Proteasome assembly chaperone 3 Proteins 0.000 description 1
101000666340 Homo sapiens Tenascin Proteins 0.000 description 1
101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102100041010 Proteasome assembly chaperone 3 Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
102100038126 Tenascin Human genes 0.000 description 1
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000008436 biogenesis Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
230000006690 co-activation Effects 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000013461 design Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229940012414 factor viia Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010037536 heparanase Proteins 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
108091005763 multidomain proteins Proteins 0.000 description 1
101150069091 nae1 gene Proteins 0.000 description 1
208000013435 necrotic lesion Diseases 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001915 proofreading effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
108010072415 tumor necrosis factor precursor Proteins 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BG107613A 2000-09-15 2003-03-06 Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена BG107613A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10045592A DE10045592A1 (de)	2000-09-15	2000-09-15	Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de)	2000-09-15	2001-09-17	Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (1)

Publication Number	Publication Date
BG107613A true BG107613A (bg)	2003-12-31

Family

ID=7656260

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107613A BG107613A (bg)	2000-09-15	2003-03-06	Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена

Country Status (22)

Country	Link
US (1)	US20040053829A1 (et)
EP (1)	EP1317556A1 (et)
JP (1)	JP2004508828A (et)
KR (1)	KR20030048041A (et)
CN (1)	CN1214115C (et)
AU (1)	AU2001293819A1 (et)
BG (1)	BG107613A (et)
BR (1)	BR0113928A (et)
CA (1)	CA2422759A1 (et)
DE (1)	DE10045592A1 (et)
EE (1)	EE200300100A (et)
HR (1)	HRP20030192A2 (et)
HU (1)	HUP0301693A3 (et)
IL (1)	IL154185A0 (et)
MX (1)	MXPA03002229A (et)
NO (1)	NO20031185L (et)
PL (1)	PL360540A1 (et)
RU (1)	RU2003106429A (et)
SK (1)	SK2812003A3 (et)
WO (1)	WO2002022833A1 (et)
YU (1)	YU18903A (et)
ZA (1)	ZA200302008B (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7468354B2 (en)	2000-12-01	2008-12-23	Genspera, Inc.	Tissue specific prodrugs
PE20021080A1 (es) *	2001-04-12	2003-02-12	Boehringer Ingelheim Int	Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de)	2001-08-31	2003-03-27	Fraunhofer Ges Forschung	Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7057026B2 (en)	2001-12-04	2006-06-06	Solexa Limited	Labelled nucleotides
DE10247755B4 (de) *	2002-10-14	2006-01-19	Pfizenmaier, Klaus, Prof. Dr.	Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2004210088A1 (en) *	2003-02-06	2004-08-19	Micromet Ag	Trimeric polypeptide construct to induce an enduring T cell response
US7374898B2 (en) *	2004-10-12	2008-05-20	The Research Foundation Of State University Of New York	Peptide inhibitors against seprase
US20090041783A1 (en)	2005-04-28	2009-02-12	Mochida Pharmaceutical Co., Ltd.	Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1736482A1 (en) *	2005-06-20	2006-12-27	INSERM (Institut National de la Santé et de la Recherche Medicale)	Recombinant trimeric 4-1BBL
DE102005036542A1 (de) *	2005-08-03	2007-02-08	Universität Stuttgart	CTL-Prodrug
EP1972350A1 (en) *	2007-03-20	2008-09-24	Rijksuniversiteit Groningen	Dual targeting system
EP2009022A1 (en) *	2007-06-26	2008-12-31	Apogenix GmbH	Trimeric death ligands with enhanced activity (tenascin)
CA3128656A1 (en)	2007-08-22	2009-02-26	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en)	2008-12-08	2014-11-25	City Of Hope	Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CN106995495A (zh)	2009-01-12	2017-08-01	希托马克斯医疗有限责任公司	修饰抗体组合物及其制备和使用方法
CN102481341B (zh) *	2009-02-23	2017-05-17	希托马克斯医疗有限公司	蛋白原及其使用方法
CA3115461A1 (en) *	2018-03-09	2019-09-12	AskGene Pharma, Inc.	Novel cytokine prodrugs
WO2019222294A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
CN113840832A (zh)	2018-05-14	2021-12-24	狼人治疗公司	可活化白介素-2多肽及其使用方法
CN112534052B (zh)	2018-07-25	2024-09-20	奥美药业有限公司	全新il-21前药及使用方法
EP3856764A4 (en)	2018-09-27	2022-11-02	Xilio Development, Inc.	MASKED CYTOKINE POLYPEPTIDES
SG11202112541RA (en)	2019-05-14	2021-12-30	Werewolf Therapeutics Inc	Separation moieties and methods and use thereof
US11845801B2 (en)	2019-06-12	2023-12-19	AskGene Pharma, Inc.	IL-15 prodrugs and methods of use thereof
JP2022545439A (ja) *	2019-08-21	2022-10-27	アスクジーン・ファーマ・インコーポレイテッド	新規ｉｌ－２１プロドラッグおよびその使用方法
EP4034551A1 (en) *	2019-09-28	2022-08-03	AskGene Pharma, Inc.	Cytokine prodrugs and dual-prodrugs
JP2023503258A (ja)	2019-11-14	2023-01-27	ウェアウルフセラピューティクス，インコーポレイテッド	活性化可能サイトカインポリペプチド及びその使用方法
JP2023553323A (ja)	2020-11-25	2023-12-21	エクシリオデベロップメント，インコーポレイテッド	腫瘍特異的に切断可能なリンカー

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1981001145A1 (en) *	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) *	1993-07-09	1996-03-26	Neuromed Technologies, Inc.	Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) *	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US5614191A (en) *	1995-03-15	1997-03-25	The United States Of America As Represented By The Department Of Health And Human Services	IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) *	1999-01-11	2000-07-13	Falkenberg Frank W	Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

2000
- 2000-09-15 DE DE10045592A patent/DE10045592A1/de not_active Withdrawn
2001
- 2001-09-17 PL PL36054001A patent/PL360540A1/xx not_active Application Discontinuation
- 2001-09-17 JP JP2002527275A patent/JP2004508828A/ja active Pending
- 2001-09-17 MX MXPA03002229A patent/MXPA03002229A/es unknown
- 2001-09-17 US US10/380,438 patent/US20040053829A1/en not_active Abandoned
- 2001-09-17 YU YU18903A patent/YU18903A/sh unknown
- 2001-09-17 AU AU2001293819A patent/AU2001293819A1/en not_active Abandoned
- 2001-09-17 WO PCT/EP2001/010730 patent/WO2002022833A1/de not_active Ceased
- 2001-09-17 CN CNB018157645A patent/CN1214115C/zh not_active Expired - Fee Related
- 2001-09-17 IL IL15418501A patent/IL154185A0/xx unknown
- 2001-09-17 HR HR20030192A patent/HRP20030192A2/hr not_active Application Discontinuation
- 2001-09-17 EP EP01974261A patent/EP1317556A1/de not_active Withdrawn
- 2001-09-17 BR BR0113928-2A patent/BR0113928A/pt not_active IP Right Cessation
- 2001-09-17 SK SK281-2003A patent/SK2812003A3/sk unknown
- 2001-09-17 KR KR10-2003-7003738A patent/KR20030048041A/ko not_active Withdrawn
- 2001-09-17 HU HU0301693A patent/HUP0301693A3/hu unknown
- 2001-09-17 EE EEP200300100A patent/EE200300100A/et unknown
- 2001-09-17 CA CA002422759A patent/CA2422759A1/en not_active Abandoned
- 2001-09-17 RU RU2003106429/13A patent/RU2003106429A/ru not_active Application Discontinuation
2003
- 2003-03-06 BG BG107613A patent/BG107613A/bg unknown
- 2003-03-12 ZA ZA200302008A patent/ZA200302008B/en unknown
- 2003-03-14 NO NO20031185A patent/NO20031185L/no unknown

Also Published As

Publication number	Publication date
NO20031185L (no)	2003-05-05
SK2812003A3 (en)	2003-11-04
ZA200302008B (en)	2004-06-25
DE10045592A1 (de)	2002-03-28
AU2001293819A1 (en)	2002-03-26
PL360540A1 (en)	2004-09-06
MXPA03002229A (es)	2005-06-20
US20040053829A1 (en)	2004-03-18
CN1458977A (zh)	2003-11-26
HUP0301693A2 (hu)	2003-08-28
EP1317556A1 (de)	2003-06-11
HRP20030192A2 (en)	2005-10-31
CA2422759A1 (en)	2003-03-17
KR20030048041A (ko)	2003-06-18
IL154185A0 (en)	2003-07-31
HUP0301693A3 (en)	2005-11-28
WO2002022833A1 (de)	2002-03-21
JP2004508828A (ja)	2004-03-25
CN1214115C (zh)	2005-08-10
RU2003106429A (ru)	2004-08-27
EE200300100A (et)	2005-02-15
YU18903A (sh)	2006-05-25
NO20031185D0 (no)	2003-03-14
BR0113928A (pt)	2003-07-22

Publication	Publication Date	Title
BG107613A (bg)	2003-12-31	Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена
CA2095836C (en)	1999-04-06	Cytokine immunoconjugates
US9775913B2 (en)	2017-10-03	Method of site specific activation of an antibody by a protease
EP1891102B1 (en)	2010-03-03	Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
US8048985B2 (en)	2011-11-01	Diphtheria toxin variant
EP0706799B1 (en)	2001-11-14	Immunoconjugates II
AU2001275246B2 (en)	2006-06-29	T cell receptor fusions and conjugates and methods of use thereof
JP2019163258A (ja)	2019-09-26	受容体媒介クリアランスが減少した、生理活性ポリペプチド単量体と免疫グロブリンＦｃ断片との結合体及びその製造方法
AU2006320858A1 (en)	2007-06-07	Methods for production of receptor and ligand isoforms
KR20150114512A (ko)	2015-10-12	대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US20120189634A1 (en)	2012-07-26	Taci as an anti-tumor agent
CN115175917A (zh)	2022-10-11	药物缀合物及其应用
NZ521629A (en)	2004-05-28	TACI as an anti-tumor agent
AU2001253920A1 (en)	2002-01-24	Use of taci as an anti-tumor agent
KR20050007359A (ko)	2005-01-17	종양 치료를 위한 면역접합체
EP0467536A2 (en)	1992-01-22	Method of treating bladder cancer cells
CN101268102A (zh)	2008-09-17	用于治疗癌症和皮肤损伤的与糖基磷脂酰肌醇(gpi)锚相连的金属蛋白酶组织抑制剂(timp)
WO2007014744A2 (en)	2007-02-08	C-terminal tnf-family ligand (ctl) -prodrug
Wüest et al.	2002	TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor
CN101914161A (zh)	2010-12-15	抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
WO2019176866A1 (ja)	2019-09-19	ウテログロビンを構造基盤とする二重特異性ポリペプチド
NZ710925B2 (en)	2021-06-29	Chimeric antigen receptor and methods of use thereof
HK1113579B (en)	2010-04-30	Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
MXPA01001970A (en)	2001-12-04	Expression and export of angiostatin and endostatin as immunofusis